Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients
NCT ID: NCT05170893
Last Updated: 2023-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
36 participants
INTERVENTIONAL
2022-01-17
2022-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of CoQ10 Administration on Hemodialysis Patients
NCT00307996
Safety and Tolerability of Coenzyme Q10 in Hemodialysis Patients
NCT00908297
Effects of Curcumin on Inflammation and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
NCT05627843
Vitamin D, Oxidative Stress and Inflammation in Hemodialysis
NCT05460338
Role of Coenzyme Q10 in Chronic Kidney Disease
NCT05942027
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Oral Coenzyme Q10 capsules daily for 12 weeks.
Coenzyme Q10
Oral capsules
Control group
Oral capsules similar to the intervention daily for 12 weeks.
Placebo
Oral capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coenzyme Q10
Oral capsules
Placebo
Oral capsules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing regular hemodialysis for at least 6 months.
Exclusion Criteria
2 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Salma AbdelRahman
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
El-Demerdash Children's Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACUC-FP-ASU RHDIRB2020110301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.